TORRENT PHARMACEUTICALS LTD. - 500420 - Compliance Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015
With reference to the above, we send herewith a copy of the Compliance Certificate under Regulation 40(9) of the SEBI (LODR) Regulations, 2015 issued by the Practicing Company Secretary, Rajesh Parekh & Co., Ahmedabad in respect of transfer of securities of the Company during the half year ended on 30th September, 2019 Kindly find the same in order. TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2019 ,inter alia, to consider and approve We would like to inform you that meeting of the Board of Directors will be held on Wednesday,23-0ct-19, inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-19. Torrent Pharma recalls 74k bottles of hypertension treatment tablets from US, Puerto Rico
Torrent Pharma recalls drugs from US, Puerto Rico: As per the report, Torrent Pharma Inc is recalling 17,088 bottles of Losartan Potassium /Hydrochlorothiazide tablets, USP 50mg/12.5mg from the same markets. Torrent Pharma down nearly 7% after USFDA sends warning letter for Gujarat facility
Torrent Pharma informed the bourses that it has received a warning letter dated 08-Oct-19 from the USFDA for its Indrad facility in Gujarat TORRENT PHARMACEUTICALS LTD. - 500420 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Mahesh AgrawalDesignation :- Company Secretary and Compliance Officer Torrent Pharmaceuticals Ltd - 500420 - Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
This is to inform that the Company has today received a warning letter dated 08-Oct-19 from the USFDA for its Indrad facility in Gujarat. This action follows the earlier intimation received from USFDA in August 2019, wherein the agency had classified its inspection as 'Official Action Indicated' (OAI). We will be engaging with the agency and are fully committed in resolving this issue at the earliest. The Company is also committed to maintaining the highest standards of compliances and quality manufacturing across all its facilities. The Company does not believe that the warning letter will have an impact of disruption of supplies or the existing revenues from operations of this facility. This is for your information and record. TORRENT PHARMACEUTICALS LTD. - 500420 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October 04, 2019 for Samir Mehta & Others Torrent Pharmaceuticals Ltd - 500420 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In compliance with the requirements under 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Compliance Certificate for half year ended on 30th September, 2019 Torrent Pharmaceuticals Ltd - 500420 - Closure of Trading Window
Pursuant to Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons of the Company (''Code'') and applicable SEBI Regulations, we would like to inform you that trading window for dealing in securities of the Company by Designated Persons stands closed from 1st October, 2019 and will be re-opened 48 hours after the submission of the Unaudited Financial Results for the Quarter ended 30th September, 2019 to the Stock Exchanges. Kindly take note of the above. TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate